NantHealth (NASDAQ:NH) Upgraded at Zacks Investment Research

Zacks Investment Research upgraded shares of NantHealth (NASDAQ:NH) from a hold rating to a buy rating in a report published on Friday morning, reports. The firm currently has $0.75 price objective on the stock.

According to Zacks, “Nant Health, LLC is a personalized healthcare company which enable improved patient outcomes and treatment decisions for critical illnesses. The company developed an adaptive learning system, CLINICS, which includes its unique software, middleware and hardware systems infrastructure that collects, indexes, analyzes and interprets of molecular, clinical, operational and financial data points derived from novel and traditional sources. Nant Health, LLC is based in CULVER CITY, United States. “

NH stock opened at $0.60 on Friday. The company has a quick ratio of 0.86, a current ratio of 0.87 and a debt-to-equity ratio of 70.81. The company has a market capitalization of $66.44 million, a PE ratio of -0.35 and a beta of 1.15. NantHealth has a 1 year low of $0.48 and a 1 year high of $3.64.

NantHealth (NASDAQ:NH) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.08). The business had revenue of $23.73 million during the quarter, compared to analysts’ expectations of $23.90 million. NantHealth had a negative return on equity of 405.21% and a negative net margin of 208.85%. Equities research analysts predict that NantHealth will post -0.53 EPS for the current fiscal year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Paloma Partners Management Co acquired a new stake in shares of NantHealth in the fourth quarter valued at $31,000. SG Americas Securities LLC acquired a new stake in shares of NantHealth in the fourth quarter valued at $29,000. Finally, Miracle Mile Advisors LLC acquired a new stake in shares of NantHealth in the first quarter valued at $27,000. Institutional investors and hedge funds own 4.68% of the company’s stock.

About NantHealth

NantHealth, Inc, together with its subsidiaries, operates as a healthcare technology company in the United States and internationally. The company engages in converging science and technology through an integrated clinical platform to provide health information at the point of care. It develops NantHealth solutions, including molecular profiling solutions, software, and hardware systems infrastructure, which integrates patient data management, bioinformatics, and molecular medicine to enable value-based care and evidence-based clinical practice.

Further Reading: How interest rates affect municipal bond prices

Get a free copy of the Zacks research report on NantHealth (NH)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for NantHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth and related companies with's FREE daily email newsletter.